|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DPY19L4 |
Gene summary for DPY19L4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DPY19L4 | Gene ID | 286148 |
| Gene name | dpy-19 like 4 | |
| Gene Alias | DPY19L4 | |
| Cytomap | 8q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024R9F2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 286148 | DPY19L4 | LZE4T | Human | Esophagus | ESCC | 4.47e-10 | 1.46e-01 | 0.0811 |
| 286148 | DPY19L4 | LZE7T | Human | Esophagus | ESCC | 5.11e-04 | 7.15e-02 | 0.0667 |
| 286148 | DPY19L4 | LZE8T | Human | Esophagus | ESCC | 4.57e-05 | 3.90e-02 | 0.067 |
| 286148 | DPY19L4 | LZE24T | Human | Esophagus | ESCC | 1.61e-07 | 1.67e-01 | 0.0596 |
| 286148 | DPY19L4 | P1T-E | Human | Esophagus | ESCC | 5.94e-06 | 1.54e-01 | 0.0875 |
| 286148 | DPY19L4 | P2T-E | Human | Esophagus | ESCC | 2.06e-17 | 3.13e-01 | 0.1177 |
| 286148 | DPY19L4 | P4T-E | Human | Esophagus | ESCC | 1.15e-12 | 3.10e-01 | 0.1323 |
| 286148 | DPY19L4 | P5T-E | Human | Esophagus | ESCC | 2.46e-08 | 5.05e-02 | 0.1327 |
| 286148 | DPY19L4 | P8T-E | Human | Esophagus | ESCC | 1.23e-14 | 2.96e-01 | 0.0889 |
| 286148 | DPY19L4 | P9T-E | Human | Esophagus | ESCC | 2.53e-08 | 8.35e-02 | 0.1131 |
| 286148 | DPY19L4 | P10T-E | Human | Esophagus | ESCC | 3.48e-21 | 2.28e-01 | 0.116 |
| 286148 | DPY19L4 | P11T-E | Human | Esophagus | ESCC | 3.05e-07 | 2.17e-01 | 0.1426 |
| 286148 | DPY19L4 | P12T-E | Human | Esophagus | ESCC | 1.22e-14 | 2.03e-01 | 0.1122 |
| 286148 | DPY19L4 | P15T-E | Human | Esophagus | ESCC | 1.83e-10 | 2.41e-01 | 0.1149 |
| 286148 | DPY19L4 | P16T-E | Human | Esophagus | ESCC | 1.04e-19 | 4.67e-01 | 0.1153 |
| 286148 | DPY19L4 | P20T-E | Human | Esophagus | ESCC | 6.93e-18 | 1.97e-01 | 0.1124 |
| 286148 | DPY19L4 | P21T-E | Human | Esophagus | ESCC | 6.30e-18 | 3.82e-01 | 0.1617 |
| 286148 | DPY19L4 | P22T-E | Human | Esophagus | ESCC | 9.67e-15 | 1.86e-01 | 0.1236 |
| 286148 | DPY19L4 | P23T-E | Human | Esophagus | ESCC | 2.98e-10 | 2.95e-01 | 0.108 |
| 286148 | DPY19L4 | P24T-E | Human | Esophagus | ESCC | 3.44e-09 | 1.27e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
| GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
| GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
| GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
| GO:00064864 | Oral cavity | OSCC | protein glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
| GO:00434134 | Oral cavity | OSCC | macromolecule glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
| GO:00700853 | Oral cavity | OSCC | glycosylation | 117/7305 | 240/18723 | 1.29e-03 | 6.42e-03 | 117 |
| GO:007008511 | Oral cavity | LP | glycosylation | 77/4623 | 240/18723 | 5.60e-03 | 3.38e-02 | 77 |
| GO:000648611 | Oral cavity | LP | protein glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
| GO:004341311 | Oral cavity | LP | macromolecule glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DPY19L4 | SNV | Missense_Mutation | c.93C>G | p.Ile31Met | p.I31M | Q7Z388 | protein_coding | tolerated(0.11) | benign(0.062) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DPY19L4 | SNV | Missense_Mutation | novel | c.1904N>A | p.Ser635Tyr | p.S635Y | Q7Z388 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DPY19L4 | SNV | Missense_Mutation | c.1732N>A | p.Ala578Thr | p.A578T | Q7Z388 | protein_coding | tolerated(0.52) | benign(0.433) | TCGA-AR-A0TV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DPY19L4 | SNV | Missense_Mutation | c.397N>C | p.Ala133Pro | p.A133P | Q7Z388 | protein_coding | tolerated(0.09) | probably_damaging(0.929) | TCGA-BH-A0DL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
| DPY19L4 | SNV | Missense_Mutation | c.437N>C | p.Ser146Thr | p.S146T | Q7Z388 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| DPY19L4 | SNV | Missense_Mutation | c.1948N>A | p.Glu650Lys | p.E650K | Q7Z388 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-GM-A3NW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
| DPY19L4 | SNV | Missense_Mutation | c.1556N>A | p.Thr519Asn | p.T519N | Q7Z388 | protein_coding | tolerated(0.4) | benign(0.242) | TCGA-EA-A411-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DPY19L4 | SNV | Missense_Mutation | c.85G>A | p.Glu29Lys | p.E29K | Q7Z388 | protein_coding | tolerated(0.14) | benign(0) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DPY19L4 | SNV | Missense_Mutation | c.916N>C | p.Tyr306His | p.Y306H | Q7Z388 | protein_coding | tolerated(0.43) | probably_damaging(0.998) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| DPY19L4 | SNV | Missense_Mutation | rs745462309 | c.1433C>A | p.Ser478Tyr | p.S478Y | Q7Z388 | protein_coding | tolerated(1) | benign(0.012) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |